Healthcare/Biotech
|
Updated on 03 Nov 2025, 11:44 am
Reviewed By
Aditi Singh | Whalesbook News Team
▶
Tragically, at least 24 children, all under five years old, have died in Madhya Pradesh over the past month after consuming adulterated cough syrup. The deaths are primarily linked to specific batches of three oral liquid medicines: Coldrif, Respifresh TR, and ReLife, which were found to contain diethylene glycol (DEG), a toxic industrial solvent. The Central Drugs Standard Control Organisation (CDSCO) confirmed the contamination but stated these batches were not exported. However, the World Health Organization (WHO) has issued a global alert, urging countries to monitor for these products.
This incident echoes similar tragedies in The Gambia, Uzbekistan, and Cameroon, where children died from Indian-made cough syrups. Experts point to systemic failures in India's pharmaceutical regulatory oversight, weak quality control, and outdated laws like the Drugs and Cosmetics Act of 1940. The infrastructure for testing is underdeveloped, and there is poor coordination between central and state drug regulators. Contract manufacturing practices and insufficient pharmacovigilance further compound these issues.
Impact: This news significantly impacts the Indian pharmaceutical sector, investor confidence in drug safety and manufacturing standards, and the country's international reputation as a reliable medicine exporter. It also highlights a critical public health and governance issue. Rating: 8/10.
Difficult Terms: Diethylene Glycol (DEG): A toxic industrial solvent that can cause severe kidney damage and death when ingested. Adulterated: Mixed with a foreign or inferior substance, often fraudulently. Regulatory Oversight: The supervision and control of an industry or activity by a regulatory authority. Pharmaceuticals: Drugs or medicines; the industry involved in their production and sale. Contract Manufacturing: When a company hires another company to produce its products, often to save costs. Pharmacovigilance: The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem.
Auto
Suzuki and Honda aren’t sure India is ready for small EVs. Here’s why.
Brokerage Reports
Stocks to buy: Raja Venkatraman's top picks for 4 November
Mutual Funds
Quantum Mutual Fund stages a comeback with a new CEO and revamped strategies; eyes sustainable growth
Tech
Why Pine Labs’ head believes Ebitda is a better measure of the company’s value
Banking/Finance
SEBI is forcing a nifty bank shake-up: Are PNB and BoB the new ‘must-owns’?
Industrial Goods/Services
India’s Warren Buffett just made 2 rare moves: What he’s buying (and selling)
Renewables
Brookfield lines up $12 bn for green energy in Andhra as it eyes $100 bn India expansion by 2030
Energy
India's green power pipeline had become clogged. A mega clean-up is on cards.